Labeled inhibitors of prostate specific membrane antigen (PSMA), biological evaluation, and use as imaging agents
US-9044468-B2 · Jun 2, 2015 · US
Conjugates for treating diseases caused by PSMA expressing cells
US9636413B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9636413-B2 |
| Application number | US-201314443212-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 14, 2013 |
| Priority date | Nov 15, 2012 |
| Publication date | May 2, 2017 |
| Grant date | May 2, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.
First claim
Opening claim text (preview).
The invention claimed is: 1. A conjugate having the formula or a pharmaceutically acceptable salt thereof. 2. A pharmaceutical composition comprising a conjugate having a formula or a pharmaceutically acceptable salt thereof. 3. The pharmaceutical composition of claim 2 , wherein the conjugate or the pharmaceutically acceptable salt thereof is present in a therapeutically effective amount for treating a disease in a host animal caused by a pathogenic population of cells, said cells expressing prostate-specific membrane antigen (PSMA). 4. The pharmaceutical composition of claim 2 , further comprising one or a plurality of additional therapeutically active compounds. 5. The pharmaceutical composition of claim 2 , further comprising one or a plurality of pharmaceutically acceptable carriers. 6. The pharmaceutical composition of claim 2 , further comprising one or a plurality of pharmaceutically acceptable diluents. 7. The pharmaceutical composition of claim 2 , further comprising one or a plurality of pharmaceutically acceptable excipients. 8. The pharmaceutical composition of claim 2 , further comprising a component selected from the group consisting of an additional therapeutically active compound, a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, a pharmaceutically acceptable excipient, and a combination thereof. 9. The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition is in bulk form. 10. The pharmaceutical composition of claim 2 , e pharmaceutical composition is a unit dose.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
of the bladder · CPC title
of the prostate · CPC title
with the first amino acid being basic · CPC title
- A61K47/542Primary
Carboxylic acids, e.g. a fatty acid or an amino acid · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9636413B2 cover?
- The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.
- Who is the assignee on this patent?
- Endocyte Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K47/542. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 02 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).